Image of Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects

LITERATURE

Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects


The gastrointestinal safety of the novel injectable cyclooxygenase-2 selective inhibitor, parecoxib sodium, was compared with the nonselective nonsteroidal anti-inflammatory drug, ketorolac, and placebo in healthy subjects.


Availability

Repacor-005Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
J Clin Gastroenterol 2004 Aug;38(7):575-80
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous